RxDoctor Payments Data

John Craver

Psychiatric/Mental Health · Foley, ALNPI 1427899897

Payments from drug & device makers

$1,391in general payments, 2019–2025

Across 63 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$355
  • Otsuka America Pharmaceutical, Inc.$237
  • Neurocrine Biosciences, Inc.$137
  • Alkermes, Inc.$134
  • Lundbeck LLC$125
  • AbbVie$106
  • plus $297 from 7 others

What the payments were for

  • Food & beverage$1,391100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,391 in reported general payments places this provider in the 55th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$3,414
Medicare patients
42
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$117,733
Invega SustennaPaliperidone Palmitate30$90,108
AristadaAripiprazole Lauroxil12$40,202
Lurasidone Hcl21$6,705
Clozapine15$1,233
Divalproex Sodium ErDivalproex Sodium33$1,080
Duloxetine Hcl24$901
Ziprasidone Hcl11$858
Buspirone Hcl50$701
Trazodone Hcl96$596
Venlafaxine Hcl ErVenlafaxine Hcl15$593
Quetiapine Fumarate38$551
Aripiprazole25$517
Mirtazapine19$448
Divalproex Sodium21$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$137$117,73313 claims
Johnson & JohnsonInvega Sustenna$74$90,10830 claims
Alkermes, Inc.Aristada$134$40,20212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Foley

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →